Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7663498 in Diabetic Retinopathy
NCT07588100Phase 1Recruiting
- Sponsor
- Roche
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7663498 in diabetic retinopathy (DR) (4 cohorts), sponsored by Roche. Primary endpoints: Percentage of Participants With Ocular Adverse Events (AEs), Percentage of Participants With Systemic (non-ocular) Adverse Events (AEs) and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
RO7663498
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT07588100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588100.